Pharma Focus Europe

Swixx Biopharma Expands into Latin America Through Acquisition and Merger with Biopas

Thursday, May 23, 2024

Swixx BioPharma AG, a global platform committed to improving access to innovative medicines worldwide, has announced its strategic expansion into Latin America. The company has finalized an agreement to acquire 100% equity of Pharma Consulting Group S.A., the parent company of Laboratorios Biopas SA. Based in Bogota, Colombia, Biopas is a leading independent marketing and distribution firm for international biopharmaceutical companies across Latin America, operating in 20 countries including Argentina, Brazil, Chile, Colombia, and Mexico. The acquisition is pending regulatory approvals, expected in June-July 2024.

This expansion follows Swixx BioPharma's entry into the Middle East in September 2023, a move towards becoming the preferred partner for biopharmaceutical companies seeking indirect routes to introduce their medicines. With Biopas' extensive coverage across Latin America, Swixx aims to provide a compelling offering spanning Central and Eastern Europe, CIS/Eurasia, MENA, and now Latin America.

Biopas' leadership team will continue to lead the combined entity in Latin America, retaining the Biopas name under the Swixx BioPharma group.

Swixx BioPharma, has extended a warm welcome to the Biopas team, expressing enthusiasm about collaborating with their talented professionals across Latin America. Lespinasse emphasizes a commitment to respecting Biopas' personnel and entrepreneurial culture, aiming to unite the two companies to create synergistic growth.

Pascal and Maria Fernanda Forget, founders of Biopas, will assume key roles within Swixx BioPharma, with Pascal serving as Executive Regional General Manager for Latin America and Maria Fernanda as Executive Operations Advisor. The Forgets will also become shareholders, with Pascal joining Swixx BioPharma's Board of Directors.

Benoit Chastaing, Non-Executive Board Member of Swixx BioPharma and Managing Partner at Merieux Equity Partners, has expressed enthusiasm for the acquisition, emphasizing its significance in creating a robust, interregional partner for global pharmaceutical companies. Chastaing believes this move offers multinational biopharma a credible alternative to direct presence in markets outside their top 20 global markets.

Pascal Forget, CEO and co-founder of Biopas, has shared his optimism about joining Swixx BioPharma, highlighting the alignment in missions and business models between the two companies. He anticipates that the collaboration will enhance their ability to bring innovative medicines to the Latin American population, fostering valuable partnerships and delivering efficient solutions to stakeholders.



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024